Skip to content
MarketScale
‹ Back to IndustriesSciences

HOW GUT HEALTH IMPACTS WHOLE BODY HEALTH

Did you know that your gut health is connected to many aspects of your overall health? It’s a very complex part of the body with 100 trillion bacteria—more than in any other part of the body. This group of bacteria is known as the gut microbiota, and they have become a particular focus for researchers…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
HOW GUT HEALTH IMPACTS WHOLE BODY HEALTH

Key takeaways

01

Did you know that your gut health is connected to many aspects of your overall health?

02

It’s a very complex part of the body with 100 trillion bacteria—more than in any other part of the body.

03

This group of bacteria is known as the gut microbiota, and they have become a particular focus for researchers…

Did you know that your gut health is connected to many aspects of your overall health? It’s a very complex part of the body with 100 trillion bacteria—more than in any other part of the body. This group of bacteria is known as the gut microbiota, and they have become a particular focus for researchers who are aiming to learn exactly how this system influences and even improves health.

Gut Microbiota is Unique for Every Individual

About 1,000 different species exist in those trillions of bacteria, representing around 5,000 specific strains. With so many kinds of bacteria, all guts are unique, but certain combinations have been found in the healthiest individuals. There are a variety of factors that impact a gut, including age, diet, genes, the environment, and medications.

What Gut Microbiota Does

Gut microbiota has several different roles in the body. It metabolizes nutrients from the food you eat and the medications you take. It also serves as a barrier against intestinal infections, and produces vitamin K, which is a building block of blood-clotting proteins. These factors are now known, but gut microbiota may do even more. Research, mostly involving animals, suggests it could be associated with overall health. The challenge is determining which actual species or strains have these unique properties.

Latest Findings Signify Microbiota is the Most Important Part of the Gastrointestinal System

New developments have been made in the study of microbiota. Two studies from the Mayo Clinic infer gut bacteria could predict if a person is more susceptible to rheumatoid arthritis (RA). Additionally, it could be a means to determine the best treatment for the condition. Researcher Veena Taneja, Ph.D. published two studies related to the subject in Genome Medicine and Arthritis and Rheumatology. The Genome Medicine published study reports that researchers were able to isolate specific bacteria that that had high populations in RA patients, while finding they were low in healthy individuals.

Cardiovascular and heart health are additional body systems connected to gut health. A study published in the Journal of Applied Microbiology links gut microbiota and gut permeability to the vascular system. In experimentation with mice, reduced levels of A muciniphila increased the likelihood of arterial plaque buildup. The findings also suggested that dietary prebiotics could increase the abundance of A muciniphila, thus decreasing plaque buildup and the resulting inflammation.

Microbiota Communicates with the Immune System

Another positive impact of balanced gut health is how the microbiota communicates with the immune system. There have already been discoveries about the relationship, and they are laying the foundation for possible future applications. More trials of probiotics and prebiotics is necessary to reach this possibility.

Probiotics Encourage Good Gut Health

The gut flora is important to a variety of the body’s functions with 70% of the immune cells located in the digestive tract. This means that gut health is essential to overall health. A healthy, well-balanced gut flora helps with digestion, protects from pathogens, delivers vitamins and nutrients, and is part of the immune system. To reap the benefits of good gut health, probiotics are vital.

Probiotics are those bacteria referred to as “good” or “beneficial.” Probiotic bacteria may be consumed in foods or supplements. When consumed through food or supplements, probiotics are able to thrive in the intestinal environment and provide benefits that aid in digestion and support normal bowel function. Learn more about probiotics and how they impact gut health by checking out this Probiotics 101.

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512